Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus
Artikel i vetenskaplig tidskrift, 2011

Single-nucleotide polymorphisms upstream of the interleukin 28B (interferon lambda 3) gene (IL28B) strongly influence treatment efficacy in patients carrying hepatitis C virus (HCV) of genotype 1. In patients receiving 12 or 24 weeks of interferon-ribavirin therapy for infection with genotype 2 or 3 (n = 341), we found that rs12979860 strikingly determined the first phase of viral elimination (P < .001). In patients treated for 24 weeks, rs12979860 also predicted the rate of sustained virologic response (P = .02), especially among those with high baseline HCV RNA levels (P = .002) or older than 45 years (P = .01). Patients carrying CCrs12979860 had higher baseline HCV RNA levels (P < .001) and did not, when treated for 12 weeks, achieve sustained virologic response more often than those carrying CTrs1297986 or TTrs1297986. The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment.

ribavirin

il28b

Författare

Magnus Lindh

Göteborgs universitet

Martin Lagging

Göteborgs universitet

Martti Färkkilä

Helsingin Yliopisto

Nina Langeland

Universitetet i Bergen

Kristine Mørch

Universitetet i Bergen

Staffan Nilsson

Göteborgs universitet

Chalmers, Matematiska vetenskaper, matematisk statistik

Gunnar Norkrans

Göteborgs universitet

Court Pedersen

University of Southern Denmark

Mads Rauning Buhl

Aarhus Universitet

Johan Westin

Göteborgs universitet

Kristoffer Hellstrand

Göteborgs universitet

Journal of Infectious Diseases

0022-1899 (ISSN) 1537-6613 (eISSN)

Vol. 203 12 1748-1752

Ämneskategorier

Dermatologi och venereologi

DOI

10.1093/infdis/jir193

Mer information

Senast uppdaterat

2018-09-06